Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is a leader in the respiratory care device market, and its increasing focus on digital health positions it well for future growth. Strong margin performance and a potential uptick in demand for its CPAP technology due to disruptions in the GLP-1 market are promising factors for the company's success. The recent acquisition of VirtuOx and management's plans for share repurchases also demonstrate its commitment to driving shareholder value. Overall, the company's strategic initiatives and positive earnings report justify a positive outlook on its stock. Financial metrics also support this, with a strong gross margin of 62.3% and an increase in its gross margin guidance for FY26. However, potential risks to achieving the target price include competition and market dynamics, as well as potential setbacks with the utilization of its CPAP technology. Given these factors, it may be prudent to remain on the sidelines for now and monitor the company's performance closely.

Bears say

ResMed is facing challenges in its growth in both its core market and its digital health initiatives. Despite strong revenue growth in certain segments, slower growth in key areas and a reliance on acquisitions for revenue growth suggest potential inefficiencies in the company's operations. An increase in competition, particularly from GLP-1 drugs and expanded OSA indications, is also expected to negatively impact PAP volumes in the medium-term. This, coupled with the company's current valuation and potential negative impacts from its shift towards digital health, lead us to maintain a Hold rating on the stock.

ResMed (RMD) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Buy based on their latest research and market trends.

According to 10 analysts, ResMed (RMD) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $292.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $292.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.